Coronary heart disease in patients with human immunodeficiency virus infection

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

According to the World Health Organization, more than 38 million people are carriers of the human immunodeficiency virus (HIV). The relative risk of cardiovascular events in patients with HIV infection is 1.5–2 times higher than those without it. An HIV-positive status is associated with a 50% increased risk of acute myocardial infarction. The mechanisms of CVD development caused by HIV activity are not fully understood, and the contribution of traditional risk factors cannot fully explain such a high potential for coronary heart disease (CHD) in patients with HIV infection. Data suggest that HIV-associated chronic inflammation and immune system activation may lead to progressive endothelial dysfunction and vascular damage. The pathogenesis of atherosclerosis and, consequently, CHD in HIV infection is extremely versatile and poorly studied. The key mechanisms in HIV-associated CHD include the effect of HIV proteins on immunocompetent cells and vascular endothelium, immunodeficiency, translocation of microorganisms from the gut, and chronic inflammation with platelet activation. Despite considerable progress in understanding HIV-associated cardiovascular disease, many unresolved questions remain. Even with effective viral suppression, inflammation and immune dysregulation appear to increase the risk of cardiovascular complications. The lack of large-scale clinical studies on the prevention and treatment of cardiovascular disease in HIV is very important. Nevertheless, some important features should be considered in the management of patients with HIV infection.

作者简介

Amina Alieva

The Russian National Research Medical University named after N.I. Pirogov

编辑信件的主要联系方式.
Email: amisha_alieva@mail.ru
ORCID iD: 0000-0001-5416-8579
SPIN 代码: 2749-6427

MD, Cand. Sci. (Med.), associate professor

俄罗斯联邦, 1, Ostrovityanova street, 117997, Moscow

Maxim Batov

P. Hertsen Moscow Oncology Research Institute — Branch of the National Medical Research Radiological Centre

Email: md.batov@gmail.com
ORCID iD: 0000-0002-3780-4358
SPIN 代码: 5850-7711

resident physician

俄罗斯联邦, Moscow

Elina Skripnichenko

The Russian National Research Medical University named after N.I. Pirogov

Email: elkaskrip@gmail.com
ORCID iD: 0000-0001-6321-8419
SPIN 代码: 3176-2080

PhD student

俄罗斯联邦, 1, Ostrovityanova street, 117997, Moscow

Natalia Teplova

The Russian National Research Medical University named after N.I. Pirogov

Email: teplova.nv@yandex.ru
ORCID iD: 0000-0002-7181-4680
SPIN 代码: 9056-1948

MD, Dr. Sci. (Med.), professor

俄罗斯联邦, 1, Ostrovityanova street, 117997, Moscow

Irina Baykova

The Russian National Research Medical University named after N.I. Pirogov

Email: 1498553@mail.ru
ORCID iD: 0000-0003-0886-6290
SPIN 代码: 3054-8884

MD, Cand. Sci. (Med.), associate professor

俄罗斯联邦, 1, Ostrovityanova street, 117997, Moscow

Ramiz Valiev

The Loginov Moscow Clinical Scientific Center

Email: radiosurgery@bk.ru
ORCID iD: 0000-0003-1613-3716
SPIN 代码: 2855-2867

MD, Cand. Sci. (Med.)

俄罗斯联邦, Moscow

Madina Akhmedova

AKFA Medline

Email: drmadina@yandex.ru
ORCID iD: 0000-0002-6184-6742
SPIN 代码: 7395-4676

MD, Cand. Sci. (Med.)

乌兹别克斯坦, Tashkent

Irina Kotikova

The Russian National Research Medical University named after N.I. Pirogov

Email: kotikova.ia@mail.ru
ORCID iD: 0000-0001-5352-8499
SPIN 代码: 1423-7300

student

俄罗斯联邦, 1, Ostrovityanova street, 117997, Moscow

Alisher Melikulov

AKFA Medline

Email: melikulov.alisher@yandex.ru
ORCID iD: 0000-0002-5164-9702
SPIN 代码: 1086-0141

MD, Dr. Sci. (Med.)

乌兹别克斯坦, Tashkent

Igor Nikitin

The Russian National Research Medical University named after N.I. Pirogov

Email: igor.nikitin.64@mail.ru
ORCID iD: 0000-0003-1699-0881
SPIN 代码: 3595-1990

MD, Dr. Sci. (Med.), professor

俄罗斯联邦, 1, Ostrovityanova street, 117997, Moscow

参考

  1. Malebranche D. HIV care has improved dramatically-but not for everyone. Nature. 2022;605(7910):S24–S25. doi: 10.1038/d41586-022-01350-6
  2. Pokrovsky VV, Ulumbekova GE, Petrachkov IV. Organization of medical care for infection caused by human immunodeficiency virus. Healthcare Management: News. Views. Education. Bulletin of VSHOUZ. 2022;8(2):108–130. (In Russ). doi: 10.33029/2411-8621-2022-8-2-108-130
  3. Patel AA, Budoff MJ. Coronary artery disease in patients with HIV infection: an update. Am J Cardiovasc Drugs. 2021;21(4):411–417. doi: 10.1007/s40256-020-00451-9
  4. Shah ASV, Stelzle D, Lee KK, et al. Global burden of atherosclerotic cardiovascular disease in people living with HIV: systematic review and meta-analysis. Circulation. 2018;138(11):1100–1112. doi: 10.1161/circulationaha.117.033369
  5. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92(7):2506–2512. doi: 10.1210/jc.2006-2190
  6. Freiberg MS, Chang CC, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013;173(8): 614–622. doi: 10.1001/jamainternmed.2013.3728
  7. Durand M, Sheehy O, Baril JG, et al. Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Quebec’s public health insurance database. J Acquir Immune Defic Syndr. 2011;57(3):245–253. doi: 10.1097/qai.0b013e31821d33a5
  8. Jong E, Louw S, van Gorp EC, et al. The effect of initiating combined antiretroviral therapy on endothelial cell activation and coagulation markers in South African HIV-infected individuals. Thromb Haemost. 2010;104(6):1228–1234. doi: 10.1160/th10-04-0233
  9. Arildsen H, Sørensen KE, Ingerslev JM, et al. Endothelial dysfunction, increased inflammation, and activated coagulation in HIV-infected patients improve after initiation of highly active antiretroviral therapy. HIV Med. 2013;14(1):1–9. doi: 10.1111/j.1468-1293.2012.01027.x
  10. Neuhaus J, Jacobs DR Jr, Baker JV, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis. 2010;201(12):1788–1795. doi: 10.1086/652749
  11. Dhawan S, Puri RK, Kumar A, et al. Human immunodeficiency virus-1-tat protein induces the cell surface expression of endothelial leukocyte adhesion molecule-1, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 in human endothelial cells. Blood. 1997;90(4):1535–1544. doi: 10.1182/blood.V90.4.1535
  12. Wang D, Melancon JK, Verbesey J, et al. Microvascular endothelial dysfunction and enhanced thromboxane and endothelial contractility in patients with HIV. J AIDS Clin Res. 2013;4(12):267. doi: 10.4172/2155-6113.1000267
  13. Tawakol A, Ishai A, Li D, et al. Association of arterial and lymph node inflammation with distinct inflammatory pathways in human immunodeficiency virus infection. JAMA Cardiol. 2017;2(2):163–171. doi: 10.1001/jamacardio.2016.4728
  14. Falcão M da C, Zírpoli JC, Albuquerque VM, et al. Association of biomarkers with atherosclerosis and risk for coronary artery disease in patients with HIV. Arq Bras Cardiol. 2012;99(5):971–978. doi: 10.1590/s0066-782x2012005000093
  15. Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011;203(6):780–790. doi: 10.1093/infdis/jiq118
  16. Qi Q, Hua S, Clish CB, et al. Plasma tryptophan-kynurenine metabolites are altered in human immunodeficiency virus infection and associated with progression of carotid artery atherosclerosis. Clin Infect Dis. 2018;67(2):235–242. doi: 10.1093/cid/ciy053
  17. Doring Y, Soehnlein O, Weber C. Neutrophil extracellular traps in atherosclerosis and atherothrombosis. Circ Res. 2017;120(4): 736–743. doi: 10.1161/circresaha.116.309692
  18. Mojoli A, Goncalves BS, Temerozo JR, et al. Neutrophil extracellular traps from healthy donors and HIV-1-infected individuals restrict HIV-1 production in macrophages. Sci Rep. 2020;10(1):19603. doi: 10.1038/s41598-020-75357-2
  19. Knight JS, Luo W, O’Dell AA, et al. Peptidylarginine deiminase inhibition reduces vascular damage and modulates innate immune responses in murine models of atherosclerosis. Circ Res. 2014; 114(6):947–956. doi: 10.1161/circresaha.114.303312
  20. Ishizaki A, Bi X, Nguyen LV, et al. Effects of short-term probiotic ingestion on immune profiles and microbial translocation among HIV-1-infected Vietnamese children. Int J Mol Sci. 2017;8(10):2185. doi: 10.3390/ijms18102185
  21. Tincati C, Douek DC, Marchetti G. Gut barrier structure, mucosal immunity and intestinal microbiota in the pathogenesis and treatment of HIV infection. AIDS Res. 2019;13:19. doi: 10.1186/s12981-016-0103-1
  22. Ouyang J, Zaongo SD, Zhang X, et al. Microbiota-meditated immunity abnormalities facilitate hepatitis b virus co-infection in people living with HIV: a review. Front Immunol. 2022;12:755890. doi: 10.3389/fimmu.2021.755890
  23. El-Far M, Tremblay CL. Gut microbial diversity in HIV infection post combined antiretroviral therapy: a key target for prevention of cardiovascular disease. Curr Opin HIV AIDS. 2018;13(1):38–44. doi: 10.1097/coh.0000000000000426
  24. Wang Z, Qi Q. Gut microbial metabolites associated with HIV infection. Future Virol. 2019;14(5):335–347. doi: 10.2217/fvl-2019-0002
  25. Hileman CO, Longenecker CT, Carman TL, et al. Elevated D-dimer is independently associated with endothelial dysfunction: a cross-sectional study in HIV-infected adults on antiretroviral therapy. Antivir Ther. 2012;17(7):1345–1349. doi: 10.3851/imp2297
  26. Sinha A, Ma Y, Scherzer R, et al. Role of T-cell dysfunction, inflammation, and coagulation in microvascular disease in HIV. J Am Heart Assoc. 2016;5(12):e004243. doi: 10.1161/jaha.116.004243
  27. Getawa S, Adane T. Coagulation parameters in human immunodeficiency virus infected patients: a systematic review and meta-analysis. AIDS Res Treat. 2022;2022:6782595. doi: 10.1155/2022/6782595
  28. Tien PC, Benson C, Zolopa AR, et al. The study of fat redistribution and metabolic change in HIV infection (FRAM): methods, design, and sample characteristics. Am J Epidemiol. 2006;163(9):860–869. doi: 10.1093/aje/kwj111
  29. Madden E, Lee G, Kotler DP, et al. Association of antiretroviral therapy with fibrinogen levels in HIV-infection. AIDS. 2008;22(6): 707–715. doi: 10.1097/QAD.0b013e3282f560d9
  30. Graham SM, Nance RM, Chen J, et al. Elevated plasma von willebrand factor levels are associated with subsequent ischemic stroke in persons with treated HIV infection. Open Forum Infect Dis. 2021;8(11):ofab521. doi: 10.1093/ofid/ofab521
  31. Funderburg NT. Markers of coagulation and inflammation often remain elevated in ART-treated HIV-infected patients. Curr Opin HIV AIDS. 2014;9(1):80–86. doi: 10.1097/coh.0000000000000019
  32. Siddiqui MA, Yamashita M. Toll-like receptor (TLR) signaling enables cyclic GMP-AMP synthase (cGAS) sensing of HIV-1 infection in macrophages. mBio. 2021;12(6):e0281721. doi: 10.1128/mBio.02817-21
  33. Hurley A, Smith M, Karpova T, et al. Enhanced effector function of CD8(+) T cells from healthy controls and HIV-infected patients occurs through thrombin activation of protease-activated receptor 1. J Infect Dis. 2013;207(4):638–650. doi: 10.1093/infdis/jis730
  34. Antoniak S, Owens AP, Baunacke M, et al. PAR-1 contributes to the innate immune response during viral infection. J Clin Invest. 2013;123(3):1310–1322. doi: 10.1172/jci66125
  35. Khawaja AA, Taylor KA, Lovell AO, et al. HIV antivirals affect endothelial activation and endothelial-platelet crosstalk. Circ Res. 2020;127(11):1365–1380. doi: 10.1161/circresaha.119.316477
  36. Alieva AM, Sozykin AV, Lyalina VV, et al. Modern view on the problem of atherosclerosis in HIV-positive people. Russian Cardiology Bulletin. 2022;17(2):25–32. (In Russ). doi: 10.17116/Cardiobulletin20221702125
  37. Feinstein MJ, Hsue PY, Benjamin LA, et al. Characteristics, prevention, and management of cardiovascular disease in people living with HIV: a scientific statement from the American Heart Association. Circulation. 2019;140(2):e98–e124. doi: 10.1161/cir.0000000000000695
  38. Peyracchia M, De Lio G, Montrucchio C, et al. Evaluation of coronary features of HIV patients presenting with ACS: the CUORE, a multicenter study. Atherosclerosis. 2018;274:218–226. doi: 10.1016/j.atherosclerosis.2018.05.001
  39. Lo J, Abbara S, Shturman L, et al. Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS. 2010;24(2): 243–253. doi: 10.1097/QAD.0b013e328333ea9e
  40. Laurent C, Marcal AL, Prieto-Gonzalez S, et al. HIV-associated vasculitis. Part II: histologic and angiographic diagnostic reconfirmation after an uncontrolled HIV infection and fatal outcome. Clin Exp Rheumatol. 2019;suppl 117(2):151–152.
  41. Fitch KV, Fulda ES, Grinspoon SK. Statins for primary cardiovascular disease prevention among people with HIV: emergent directions. Curr Opin HIV AIDS. 2022;17(5):293–300. doi: 10.1097/coh.0000000000000752
  42. O’Dwyer EJ, Bhamra-Ariza P, Rao S, et al. Lower coronary plaque burden in patients with HIV presenting with acute coronary syndrome. Open Heart. 2016;3(2):e000511. doi: 10.1136/openhrt-2016-000511
  43. Theodoropoulos K, Mennuni M, Sartori S, et al. Quantitative angiographic characterisation of coronary artery disease in patients with human immunodeficiency virus (HIV) infection undergoing percutaneous coronary intervention. EuroIntervention. 2017;12(14):1757–1765. doi: 10.4244/eij-d-15-00409
  44. Becker AC, Sliwa K, Stewart S, et al. Acute coronary syndromes in treatment-naïve black south africans with human immunodeficiency virus infection. J Interv Cardiol. 2010;23(1):70–77. doi: 10.1111/j.1540-8183.2009.00520.x
  45. Perelló R, Calvo M, Miró O, et al. Clinical presentation of acute coronary syndrome in HIV infected adults: a retrospective analysis of a prospectively collected cohort. Eur J Intern Med. 2011;22(5): 485–488. doi: 10.1016/j.ejim.2011.02.017
  46. Nadel J, O’Dwyer E, Emmanuel S, et al. High-risk coronary plaque, invasive coronary procedures, and cardiac events among HIV-positive individuals and matched controls. J Cardiovasc Comput Tomogr. 2016;10(5):391–397. doi: 10.1016/j.jcct.2016.07.018
  47. Vachiat A, McCutcheon K, Tsabedze N, et al. HIV and ischemic heart disease. J Am Coll Cardiol. 2017;69(1):73–82. doi: 10.1016/j.jacc.2016.09.979
  48. Hauguel-Moreau M, Boccara F, Boyd A, et al. Platelet reactivity in human immunodeficiency virus infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVERE2ST-HIV study. Eur Heart J. 2017;38(21):1676–1686. doi: 10.1093/eurheartj/ehw583
  49. McCutcheon K, Triantafyllis AS, Van den Eynde J, et al. Coronary revascularization in patients with HIV. Trends Cardiovasc Med. 2022;32(3):163–169. doi: 10.1016/j.tcm.2021.02.006
  50. Smilowitz NR, Gupta N, Guo Y, et al. Influence of human immunodeficiency virus seropositive status on the in-hospital management and outcomes of patients presenting with acute myocardial infarction. J Invasive Cardiol. 2016;28(10):403–409.
  51. Peyracchia M, Verardi R, Rubin SR, et al. In-hospital and long-term outcomes of HIV-positive patients undergoing PCI according to kind of stent: a meta-analysis. J Cardiovasc Med (Hagerstown). 2019;20(5):321–326. doi: 10.2459/JCM.0000000000000767
  52. Ren X, Trilesskaya M, Kwan DM, et al. Comparison of outcomes using bare metal versus drug-eluting stents in coronary artery disease patients with and without human immunodeficiency virus infection. Am J Cardiol. 2009;104(2):216–222. doi: 10.1016/j.amjcard.2009.03.036
  53. Yanagawa B, Verma S, Dwivedi G, et al. Cardiac surgery in HIV patients: state of the Art. Can J Cardiol. 2019;35(3):320–325. doi: 10.1016/j.cjca.2018.11.006
  54. Wollner G, Zimpfer D, Manduric M, et al. Outcomes of coronary artery bypass grafting in patients with human immunodeficiency virus infection. J Card Surg. 2020;35(10):2543–2549. doi: 10.1111/jocs.14828
  55. Dominici C, Chello M. Impact of human immunodeficiency virus (HIV) infection in patients undergoing cardiac surgery: a systematic review. Rev Cardiovasc Med. 2020;21(3):411–418. doi: 10.31083/j.rcm.2020.03.104
  56. Poznyak AV, Bezsonov EE, Borisov EE, et al. Atherosclerosis in HIV patients: what do we know so far? Int J Mol Sci. 2022;23(5):2504. doi: 10.3390/ijms23052504
  57. Leyes P, Cofan M, González-Cordón A, et al. Increased cholesterol absorption rather than synthesis is involved in boosted protease inhibitor-associated hypercholesterolaemia. AIDS. 2018;32(10): 1309–1316. doi: 10.1097/qad.0000000000001837
  58. Mulligan K, Grunfeld C, Tai VW, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr. 2000;23(1):35–43. doi: 10.1097/00126334-200001010-00005
  59. Martinez E, Gonzalez-Cordon A, Ferrer E, et al. Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir. HIV Med. 2014;16(6):330–338. doi: 10.1111/hiv.12121
  60. Jain RG, Furfine ES, Pedneault L, et al. Metabolic complications associated with antiretroviral therapy. Antiviral Res. 2001;51(3): 151–177. doi: 10.1016/S0166-3542(01)00148-6
  61. Palacios R, Pérez-Hernández IA, Martínez MA, et al. Efficacy and safety of switching to abacavir/lamivudine (ABC/3TC) plus rilpivirine (RPV) in virologically suppressed HIV-infected patients on HAART. Eur J Clin Microbiol Infect Dis. 2016;36(5):815–819. doi: 10.1007/s10096-016-2602-3
  62. Myerson M, Malvestutto C, Aberg JA. Management of lipid disorders in patients living with HIV. J Clin Pharmacol. 2015;55(9): 957–974. doi: 10.1002/jcph.473
  63. Lagathu C, Béréziat V, Gorwood J, et al. Metabolic complications affecting adipose tissue, lipid and glucose metabolism associated with HIV antiretroviral treatment. Expert Opin Drug Saf. 2019;18(9): 829–840. doi: 10.1080/14740338.2019.1644317
  64. Thompson MA, Horberg MA, Agwu AL, et al. Primary care guidance for persons with human immunodeficiency virus: 2020 update by the HIV medicine association of the infectious diseases society of America. Clin Infect Dis. 2021;73(11):e3572–e3605. doi: 10.1093/cid/ciaa1391
  65. Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV medicine association of the infectious disease society of America and the adult. Clin Infect Dis. 2003;37(5):613–627. doi: 10.1086/378131
  66. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS. 2002;16(4):569–577. doi: 10.1097/00002030-200203080-00008
  67. Vavlukis M, Vavlukis A. Adding ezetimibe to statin therapy: latest evidence and clinical implications. Drugs Context. 2018;7:212534. doi: 10.7573/dic.212534
  68. Jacobson TA, Maki KC, Orringer CE, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 2. J Clin Lipidol. 2015;9(Suppl 6):S1–S122. doi: 10.1016/j.jacl.2015.09.002

补充文件

附件文件
动作
1. JATS XML
下载
2. Fig. 1. Etiopathogenesis of HIV-associated coronary heart disease.

下载 (525KB)
索引源数据

版权所有 © Alieva A.M., Batov M.A., Skripnichenko E.A., Teplova N.V., Baykova I.E., Valiev R.K., Akhmedova M.F., Kotikova I.A., Melikulov A.A., Nikitin I.G., 2023

Creative Commons License
此作品已接受知识共享署名-非商业性使用-禁止演绎 4.0国际许可协议的许可。
 


##common.cookie##